Loading...
Loading...
- Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc CHRS have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC).
- As of October 31, 2021, at the final analysis, a significant improvement in PFS was detected in the toripalimab arm over the placebo arm, with a median PFS of 8.4 vs. 5.6 months.
- The 1-year PFS rates for the toripalimab and placebo arms were 36.7% and 17.2%, respectively.
- Related: Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer.
- A prespecified interim analysis demonstrated a statistically significant improvement in overall survival for the toripalimab arm over the placebo arm (median OS not reached vs. 17.1 months).
- The addition of toripalimab to standard first-line chemotherapy in patients with advanced NSCLC showed a manageable safety profile with no new safety signals observed.
- Price Action: CHRS shares are up 5.51% at $12.73 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in